3650 results for «248»
3650 results
FFR and non-hyperaemic pressure ratios
20 May 2026 – From EuroPCR 2026
This session presents contemporary clinical applications of fractional flow reserve (FFR) and non-hyperaemic pressure ratios (NHPR), highlighting real-world impacts of physiology microcatheter-based indices, the interplay between epicardial stenosis and microvascular resistance, post-PCI hyperemia effects on iFR, and machine-learning driven outcome predictions.
Other right-sided and tricuspid valve interventions
20 May 2026 – From EuroPCR 2026
This session focuses on right-sided heart valve interventions, particularly targeting tricuspid valve disease. Topics include clinical outcomes in atrial functional tricuspid regurgitation, management in the context of left-sided valvular disease, treatment approaches for tricuspid valve endocarditis, and advances in transcatheter therapies and device placements.
Insights from real world TAVI practice
20 May 2026 – From EuroPCR 2026
This session presents comprehensive insights from real-world transcatheter aortic valve implantation (TAVI) practice, including sex differences in coronary assessment, the impact of general anesthesia on aortic valve gradients, early rehospitalisation rates, and the management of TAVI in patients with prior hip arthroplasty. Additionally, it explores multinational...
Continual refinement in LAA closure
20 May 2026 – From EuroPCR 2026
This session presents the latest advancements in left atrial appendage closure (LAAC). It covers new risk scoring systems, sex-specific outcome analyses, safety in elderly populations, and comparative data between LAMBRE and WATCHMAN devices from a high-volume center, highlighting continual refinement in LAAC strategies.
New frontiers in coronary disease treatment
21 May 2026 – From EuroPCR 2026
Examine recent advances in coronary disease treatment focusing on drug-eluting stents versus drug-coated balloon strategies. This session presents real-world data on lesion preparation, sex-specific outcomes, physiological disease patterns, and procedural factors influencing PCI success.
Pharmacology without borders, from coronary artherostenosis to radial artery
21 May 2026 – From EuroPCR 2026
This session delves into the expansive role of pharmacology in interventional cardiology, addressing topics ranging from coronary atherostenosis to radial artery management. Key discussions include the real-world efficacy and safety of intravenous cangrelor-assisted PCI in chronic coronary syndromes, comparative analysis of intra-arterial verapamil versus placebo for...
Focus on heart failure: from acute to chronic
21 May 2026 – From EuroPCR 2026
This comprehensive session delves into the spectrum of heart failure management, from acute presentations to chronic conditions. Key topics include the cardio-hepatic syndrome and right ventricular dysfunction in HFmrEF, prognostic implications of heart failure etiologies, and innovative approaches such as AI-assisted echocardiography for early detection of...
Strategies to enhance bifurcation PCI outcomes
21 May 2026 – From EuroPCR 2026
This session addresses strategies to optimize outcomes in coronary bifurcation PCI. It evaluates the impact of cutting and scoring balloons versus non-compliant balloons on stent expansion, predictors of target vessel revascularization using the POKI technique, and compares stent and non-stent approaches in side branch myocardial infarction...
RESHAPE-HF2 - Percutaneous repair of moderate-to-severe or severe functional mitral regurgitation in patients with symptomatic heart failure
01 Sep 2024
Nicola Ryan provides her take on the RESHAPE-HF2 trial presented by Stefan Anker at the ESC Congress 2024 in London and simultaneously published in the NEJM.
The RESHAPE-HF 2 trial is a prospective randomised control trial comparing transcatheter mitral valve repair (TEER) and guideline-directed medical therapy to guideline-directed medical...
Author
Insights from the Corevalve US Pivotal and SURTAVI trials
05 Apr 2022
Pierre Deharo and Giuseppe Di Gioia provide their take on this analysis of the 5 years incidence, outcomes and predictors of hemodynamic SVD in patients undergoing TAVI and surgery from the Corevalve US Pivotal and SURTAVI trials.
Author
Author
